Merck’s Suvorexant rouses insomnia but must outperform generics to shine
This article was originally published in Scrip
On 8 November, the FDA accepted for standard review an NDA application for suvorexant; Merck’s potential first-in-class treatment for insomnia. The candidate will be evaluated by the FDA’s Controlled Substance Staff during NDA review, and if approved, will become available after a schedule assessment and determination has been completed by the US Drug Enforcement Administration. Suvorexant is an orexin receptor antagonist and therefore represents a novel mechanism of action in the insomnia pipeline.
You may also be interested in...
Merck & Co created a stir with its the Phase II C-WORTHy study at European Association for the Study of the Liver in London on 10 April. Datamonitor Healthcare analyst Michael Haydock gives his take on the data.
Antimicrobial resistance (AMR) is a spreading phenomenon that threatens to increase healthcare expenditure as previously treatable infections become significant sources of morbidity. Despite this looming crisis, the pipeline of antimicrobial drugs has dwindled greatly in recent years as low prices and the reservation of new products for later lines of therapy reduce the commercial return on investment in this area. In order to encourage pharmaceutical investment in the antimicrobial pipeline, significant commercial and regulatory barriers must be addressed. Governments must provide subsidies for the development of novel products, while regulators could ease the path to the market with the acceptance of smaller datasets and higher premiums for products addressing unmet needs.